SUR1 receptor interaction with hesperidin and linarin predicts possible mechanisms of action of Valeriana officinalis in Parkinson
MetadataShow full item record
Parkinson's disease (PD) is one of the most common neurodegenerative disorders. A theoretical approach of our previous experiments reporting the cytoprotective effects of the Valeriana officinalis compounds extract for PD is suggested. In addiction to considering the PD as a result of mitochondrial metabolic imbalance and oxidative stress, such as in our previous in vitro model of rotenone, in the present manuscript we added a genomic approach to evaluate the possible underlying mechanisms of the effect of the plant extract. Microarray of substantia nigra (SN) genome obtained from Allen Brain Institute was analyzed using gene set enrichment analysis to build a network of hub genes implicated in PD. Proteins transcribed from hub genes and their ligands selected by search ensemble approach algorithm were subjected to molecular docking studies, as well as 20 ns Molecular Dynamics (MD) using a Molecular Mechanic Poison/Boltzman Surface Area (MMPBSA) protocol. Our results bring a new approach to Valeriana officinalis extract, and suggest that hesperidin, and probably linarin are able to relieve effects of oxidative stress during ATP depletion due to its ability to binding SUR1. In addition, the key role of valerenic acid and apigenin is possibly related to prevent cortical hyperexcitation by inducing neuronal cells from SN to release GABA on brain stem. Thus, under hyperexcitability, oxidative stress, asphyxia and/or ATP depletion, Valeriana officinalis may trigger different mechanisms to provide neuronal cell protection. © 2016 Santos, Giraldez-Alvarez, ávila-Rodriguez, Capani, Galembeck, Neto, Barreto and Andrade.
Showing items related by title, author, creator and subject.
ArticleJurado-Coronel J.C.; Ávila-Rodriguez M.; Echeverria V.; Hidalgo O.A.; Gonzalez J.; Aliev G.; Barreto G.E. (Bentham Science Publishers, 2016)
Targeting the nicotinic acetylcholine receptors (nAChRs) in astrocytes as a potential therapeutic target in Parkinson’s disease (2020) Jurado-Coronel J.C.; Ávila-Rodriguez M.; Capani F.; Gonzalez J.; Morán V.E.; Barreto G.E. (Bentham Science Publishers, 2016)
Structure/activity analysis of task-3 channel antagonists based on a 5,6,7,8 tetrahydropyrido[4,3-d]pyrimidine (2020) Ramírez D.; Bedoya M.; Kiper A.K.; Rinné S.; Morales-Navarro S.; Hernández-Rodríguez E.W.; Sepúlveda F.V.; Decher N.; González W. (MDPI AG, 2019)